Skip to main content

Table 4 Cox multivariable models for time to progression and overall survival a

From: TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

   

Time to progression

   

Overall survival

  

Risk factor

n

HR

95% CI

 

P

HR

95% CI

 

P

Regimen (GD vs. D)

 

0.60

(0.42-

0.84)

0.003

0.88

(0.67-

1.15)

0.34

TIMP-1 (positive vs. negative)

 

0.82

(0.55-

1.21)

0.31

0.71

(0.52-

0.98)

0.03

PAM50

    

0.007

   

0.0001

  Luminal A

78

0.68

(0.45-

1.04)

0.08

0.78

0.56

1.08

0.14

  Luminal B

100b

1.00

referent

  

1.00

referent

  

  Basal-like

40

1.75

(1.05-

2.92)

0.03

2.39

(1.56-

3.64)

<0.0001

  HER2-enriched

46

1.30

(0.82-

2.07)

0.27

1.25

(0.85-

1.84)

0.25

Visceral disease (yes vs. no)

 

1.60

(1.07-

2.39)

0.02

1.13

(0.84-

1.53)

0.42

Stage of disease (locally advanced vs. metastatic)

1.96

(1.02-

3.76)

0.04

0.72

(0.42-

1.24)

0.23

Metastatic sites (3+ vs. 1-2)

 

1.24

(0.86-

1.77)

0.25

1.52

(1.13-

2.04)

0.01

ECOG performance status (2 vs. 0-1)

 

1.19

(0.85-

1.67)

0.31

1.47

(1.12-

1.93)

0.006

  1. aModels stratified for previous chemotherapy (none, n = 76; adjuvant, n = 86; locally advanced or metastatic, n = 102).
  2. bIncluding 6 records with missing value of PAM50 molecular subtype.
  3. Abbreviations: CI Confidence interval, D Docetaxel, ECOG Eastern Cooperative Oncology Group, G Gemcitabine, HER2 Human epidermal growth factor receptor 2, HR Hazard ratio, TIMP-1 Tissue inhibitor of metalloproteinases-1.